PRODUCTS
SERVICES
COMPANY
CONTACT
FAQ
Search
Dictionary
Mobile
Login
Login/Nickname:
Password:
Remember login
Login
Send password reminder...
Fred Saad Selected Research
Hormones
08/2008
The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
08/2008
Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer.
11/2007
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.
08/2007
Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer.
06/2006
Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer.
04/2006
Therapeutic approach to hormone-refractory prostate cancer.
01/2006
Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
02/2005
The role of bisphosphonates in hormone-refractory prostate cancer.
06/2004
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
10/2002
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Articles by Research Topic
Disease
35
Prostatic Neoplasms (Prostate Cancer)
08/2008 - 12/2002
10
Neoplasm Metastasis (Metastasis)
07/2008 - 02/2004
3
Neoplasms (Cancer)
07/2008 - 04/2005
2
Bone Resorption
07/2008 - 08/2005
2
Pain (Aches)
04/2008 - 08/2002
2
Urogenital Neoplasms
06/2006 - 11/2005
1
Renal Cell Carcinoma (Grawitz Tumor)
06/2007
1
Spinal Cord Compression
06/2007
1
Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
08/2005
1
Spontaneous Fractures (Pathological Fracture)
12/2002
1
Carcinoma (Carcinomatosis)
10/2002
Drug/Important Bio-Agent (IBA)
14
zoledronic acid (zoledronate)
FDA Link
07/2008 - 10/2002
10
Hormones
IBA
08/2008 - 10/2002
6
Diphosphonates
IBA
05/2006 - 09/2003
3
Androgen Receptors (Androgen Receptor)
IBA
05/2008 - 09/2006
3
Prostate-Specific Antigen (Semenogelase)
IBA
07/2007 - 05/2005
3
NF-kappa B (NF-kB)
IBA
12/2005 - 02/2004
2
docetaxel (Taxotere)
FDA Link
08/2008 - 08/2008
1
Mitoxantrone (Novantrone)
FDA Link
Generic
08/2008
1
Prednisone (Sone)
FDA Link
Generic
08/2008
1
Carbon Monoxide
IBA
05/2008
1
RANK Ligand
IBA
05/2008
1
Receptor Activator of Nuclear Factor-kappa B (TRANCE-R)
IBA
05/2008
1
Biological Markers (Surrogate Marker)
IBA
12/2007
1
atrasentan
IBA
11/2007
1
Clodronic Acid (Clodronate)
IBA
11/2007
1
sunitinib (Sutent)
FDA Link
06/2007
1
NF-kappa B p52 Subunit
IBA
05/2007
1
I-kappa B Kinase
IBA
01/2007
1
Transcription Factors (Transcription Factor)
IBA
01/2007
1
Phytic Acid (Inositol Hexaphosphate)
IBA
09/2006
1
Casein Kinase II (Casein Kinase 2)
IBA
12/2005
1
alfuzosin (UroXatral)
FDA Link
08/2005
1
Lidocaine (Xylocaine)
FDA Link
Generic
08/2002
Therapy/Procedure
4
Prostatectomy (Retropubic Prostatectomy)
08/2008 - 08/2007
1
Aftercare (After-Treatment)
09/2006